U
Ultragenyx Pharmaceutical Inc. (RARE)
NMS – Real vaqt narxi. Valyuta: USD
26.84
+0.54 (2.05%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
26.84
+0.54 (2.05%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Ultragenyx Pharmaceutical Inc., biotexnologiya kompaniyasi, Shimoliy Amerika, Lotin Amerikasi, Yevropa, Yaqin Sharq, Afrika va Osiyo-Tinch okeani mintaqalarida noyob va o'ta noyob genetik kasalliklarni davolash uchun yangi mahsulotlarni aniqlash, sotib olish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning biologik mahsulotlari orasida X-ga bog'liq gipofosfatemiya va o'smadan kelib chiqqan osteomalaziya davolash uchun fibroblast o'sish omili 23 ga qarshi antitelani o'z ichiga olgan Crysvita (burosumab), Mukopolisakkaridoz VII bilan bolalar va kattalarni davolash uchun ferment o'rnini bosuvchi terapiya Mepsevii, uzun zanjirli yog' kislotalari oksidlanishining buzilishlarini davolash uchun Dojolvi va gomozigota oilaviy giperxolesterolemiyani davolash uchun Evkeeza (evinacumab) mavjud. Kompaniyaning 3-bosqich klinik sinovlarida bo'lgan mahsulot nomzodlari orasida osteogenezis imperfekta davolash uchun inson monoklonal antikori UX143, Sanfilippo sindromi A turi yoki MPS IIIA, noyob lizosomal saqlash kasalligi bilan og'rigan bemorlarni davolash uchun AAV9 gen terapiyasi mahsuloti nomzodi UX111, glikogen saqlash kasalligi tip Ia bilan og'rigan bemorlarni davolash uchun adeno-assotsiatsiyalangan virus 8 (AAV8) gen terapiyasi klinik nomzodi DTX401, ornitin transkarbamilaza bilan og'rigan bemorlarni davolash uchun AAV8 gen terapiyasi DTX301 va Angelman sindromini davolash uchun antisense oligonukleotid GTX-102 mavjud. Shuningdek, u Uilson kasalligini davolash uchun 2-bosqich klinik sinovida bo'lgan UX701 va glikogen saqlash kasalligi III tipini davolash uchun UX053 ni ishlab chiqadi. Ultragenyx Pharmaceutical Inc. Kyowa Kirin Co., Ltd., Sent-Luis universiteti, Baylor tadqiqot instituti, REGENXBIO Inc., GeneTx, Mereo, Pensilvaniya universiteti, Solid Biosciences Inc., Regeneron, Abeona va Arcturus Therapeutics Holdings Inc. bilan hamkorlik va litsenziyalash shartnomalariga ega. Kompaniya 2010 yilda ro'yxatga olingan va Kaliforniyaning Novato shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | rare-20260331.htm |
| 2026-05-05 | 8-K | rare-20260505.htm |
| 2026-04-02 | 8-K | rare-20260402.htm |
| 2026-03-30 | 8-K | rare-20260330.htm |
| 2026-03-27 | DEFA14A | rare015368-defa14a.htm |
| 2026-03-12 | 8-K | rare-20260312.htm |
| 2026-02-23 | 8-K | rare-20260223.htm |
| 2026-02-18 | 10-K | rare-20251231.htm |
| 2026-02-12 | 8-K | rare-20260212.htm |
| 2026-02-03 | 8-K | rare-20260203.htm |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs |